Free Trial

VolitionRx Q2 2023 Earnings Report

VolitionRx logo
$0.68 +0.09 (+16.33%)
(As of 12/20/2024 05:31 PM ET)

VolitionRx EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$0.29 million
Beat/Miss
Missed by -$70.00 thousand
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Q2 2023
Time
N/A
Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

VolitionRx Earnings Headlines

VolitionRx’s Nu.Q cancer test shows efficacy in lung cancer detection
This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Q3 2024 VolitionRX Ltd Earnings Call Transcript
VolitionRx files $100M mixed securities shelf
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSEAMERICAN:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat

Upcoming Earnings